Learn More
Resistance to endocrine therapy is a major complication of luminal breast cancer and studies of the biological features of hormonal resistance are limited by the lack of adequate preclinical models. The aim of this study is to establish and characterize a panel of primary human luminal breast carcinoma xenografts, and to evaluate their response to endocrine(More)
Genome wide expression analyses techniques are now applied to breast carcinoma. Several results have been achieved : molecular clustering of breast carcinomas, implementation of powerful prognostic classifications, and in some way predictive classification. Unfortunately, translation to bedside remains limited due to standardization difficulties.
L’incidence des tumeurs (T) du sein pT1abN0 est en aug‐ mentation, en lien avec les programmes de dépistage. Si elles sont globalement de très bon pronostic, avec une sur‐ vie à cinq ans supérieure à 90 %, il a été montré que celles surexprimant HER2 et ne recevant pas de traitement systé‐ mique adjuvant sont associées à un pronostic plus péjoratif [1,2].(More)
Despite the improvement in surgical management for ovarian carcinoma, it remains the most aggressive gynaecologic cancer with the ability to kill patients. Finding new treatments that can improve survival rate is an urgent need for these patients. Antiangiogenics with bevacizumab in association with chemotherapy has demonstrated their capability to decrease(More)
To investigate the efficacy and the safety of gemcitabine and oxaliplatin combination in metastatic breast cancer (MBC), in patients heavily treated with anthracycline and taxane. A retrospective study including all MBC patients, treated by two different schedules of GemOx between February 2001 and December 2003 in the medical oncology department of(More)
A CONTROVERSIAL SUBJECT: Several large randomised studies have demonstrated a reduction in mortality due to breast cancer of around 30% in women aged over 50, with the development of systematic mammography. There are data also suggesting an identical benefit in women aged 40 to 49, when screening is intensified. A recent meta-analysis has contradicted the(More)
  • 1